The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last ...

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

Evolution and innovation are critical to the field of life sciences, with each year bringing new challenges and breakthroughs ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

SIFI, an Italian ophthalmology company focused mostly on the European market, doesn’t normally make it out to San Francisco ...

The story of HCPs’ advocacy for the Treat and Reduce Obesity Act reveals a broader truth: HCPs care deeply about the ...

The Tony Blair Institute for Global Change, recently estimated that AI could significantly impact the UK job market, ...